Biocon says Malaysia insulin plant passed HPRA inspection


Biocon says its insulin plant in Malaysia has been awarded a European GMP certificate after an inspection by Ireland’s Health Products Regulatory Authority (HPRA).

The drug maker announced its receipt of the certificate in a Bombay Stock Exchange (BSE) filing last week, explaining the site in Johor successfully passed an HPRA audit in April.

The facility – which makes insulin active pharmaceutical ingredient (API), insulin analogues and finished products - is located at the Bio-XCell biotechnology park.

Construction plans were first announced in 2011 when Biocon said the plant would produce insulin for Pfizer under a 2010 contract.

The plant became operational after it was commissioned in 2015.

In May, Malaysia’s Ministry of Health contracted awarded Biocon a three-year contract to supply recombinant insulin made at the facility to healthcare clinics and hospitals across the country.

The HPRA's public relations agency did not respond to a request for confirmation.

Regulatory issue

Approval for the Malaysia site comes months after Biocon’s plant in Bangalore, India – which also makes biosimilars – was criticised by European and US regulators.

An inspection in March by France’s regulatory body ANSM (Agence Nationale de Sécurité du Médicament) resulted in a statement of non-compliance with GMP being issued to the Biocon in July, citing 35 issues at the facility.

A month later withdraw dossiers for trastuzumab and pegfilgrastim biosimilars it had previously filed with the European Medicines Agency (EMA).

And last month the FDA issued Biocon with a Form 483 with ten deviations observed during an inspection of the Bangalore facility in May and June.


HPRA told us "Following an inspection carried out at the request of the European Medicines Agency, a GMP certificate has been issued to the Biocon plant in Malaysia. The certificate is dated 6th September 2017 and has been uploaded to the EUdraGMDP database."

Related News

Image: iStock/cbies

Mylan's EU biosimilar ambition hit by GMP issues at Biocon plant

Image: iStock/Tuomas_Lehtinen

US FDA sends Biocon Bangalore plant 483 with 8 observations

The approval will open doors for Biocon in more than 15 European countries. (Image: iStock)

Biocon receives first generic approval in EU

Image: iStock/XtockImages

Biocon: Three-month US FDA trastuzumab biosimilar delay not related to cGMP issues

Biocon buys Vizag API plant from supplier Acacia

Biocon buys Vizag API plant from supplier Acacia

Image: iStock/EikoTsuttiy

Mylan and Biocon Neulasta biosimilar to go under US FDA scrutiny

Image: iStock/chingraph

Biocon wins $68m Malaysian contract for biosimilar insulin and pen supply


US FDA finds faults at Biocon plant slammed by French regulators in July

Image: Google Streetview

Biocon Malaysia insulin plant set to supply Lantus biosimilar under EU review

Related Products

See more related products